Sökning: onr:"swepub:oai:DiVA.org:uu-425647" >
SABINA :
SABINA : An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
-
- Janson, Christer (författare)
- Uppsala universitet,Lung- allergi- och sömnforskning
-
- Menzies-Gow, Andrew (författare)
- Royal Brompton Hosp, Lung Div, London, England
-
- Nan, Cassandra (författare)
- AstraZeneca, Biopharmaceut Med, Gothenburg, Sweden
-
visa fler...
-
- Nuevo, Javier (författare)
- AstraZeneca, Biopharmaceut Med, Serrano Galvache 56, Madrid 28033, Spain
-
- Papi, Alberto (författare)
- Univ Ferrara, Dept Med Sci, Ferrara, Italy
-
- Quint, Jennifer K. (författare)
- Imperial Coll London, Natl Heart & Lung Inst, Resp Epidemiol Occupat Med & Publ Hlth, London, England
-
- Quirce, Santiago (författare)
- La Paz Univ Hosp, Dept Allergy, Madrid, Spain; CIBER Resp Dis CIBERES, Madrid, Spain
-
- Vogelmeier, Claus F. (författare)
- Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, Dept Med Pulm & Crit Care Med, Marburg, Germany; German Ctr Lung Res DZL, Marburg, Germany
-
visa färre...
-
(creator_code:org_t)
- 2020-01-24
- 2020
- Engelska.
-
Ingår i: Advances in Therapy. - : Springer Science and Business Media LLC. - 0741-238X .- 1865-8652. ; 37:3, s. 1124-1135
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- IntroductionGlobally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program.MethodsPrescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year.ResultsMore than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries.ConclusionsThe findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- Europe
- Overreliance
- Prescription
- Public health
- Short-acting beta2-agonist
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas